Cytovance Biologics, a contract development and manufacturing organization (CDMO), announces the appointment of Jesse McCool to the position of CEO.
Dr McCool replaces Yan Wang, who had held the role of interim CEO alongside the position of director of the board. Dr McCool had been with the company since 2013 – joining as VP of microbial services before rising to become chief technology officer and now CEO.
Prior to joining Cytovance, Dr McCool had worked at Lonza as director of process development.
Yan Wang said, “Dr McCool’s depth of knowledge of our industry, professional reputation and professional network have helped to propel Cytovance into a leading CDMO that is well recognized for responsiveness, reliability and resourcefulness.”